Pramlintide is an analog of human amylin. Amylin is co-secreted with insulin from pancreatic beta cells and acts centrally to slow gastric emptying, suppress postprandial glucagon secretion, and decrease food intake. These actions complement those of insulin to regulate blood glucose concentrations. Amylin is relatively deficient in patients with type 2 diabetes, depending on the severity of beta-cell secretory failure, and is essentially absent in patients with type 1 diabetes. Through mechanisms similar to those of amylin, pramlintide improves overall glycemic control, reduces postprandial glucose levels, and reduces bodyweight in patients with diabetes using mealtime insulin. SYMLIN® (pramlintide acetate) is indicated for patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve desired glycemic control despite optimal insulin therapy.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SYMLIN Approved UseSYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. Launch Date1.11093114E12 |
Sample Use Guides
•Upon initiation of SYMLIN® (pramlintide acetate), reduce mealtime insulin dose by 50%. Monitor glucoses frequently and individualize subsequent insulin dose adjustments.
•Type 1 Diabetes: Start at 15 mcg subcutaneously before major meals. Increase in 15 mcg increments to a maximum premeal dose of 30 or 60 mcg; if not tolerated, reduce to 30 mcg, as tolerated.
•Type 2 Diabetes: Start at 60 mcg subcutaneously before major meals then increase to 120 mcg before meals, as tolerated.
•Wait at least 3 days between dose titrations to minimize nausea.
Route of Administration:
Other
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Jun 26 17:09:03 UTC 2021
by
admin
on
Sat Jun 26 17:09:03 UTC 2021
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
D3FM8FA78T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29711
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
||
|
WHO-VATC |
QA10BX05
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
||
|
NDF-RT |
N0000177910
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
||
|
WHO-ATC |
A10BX05
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
||
|
LIVERTOX |
790
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
||
|
NDF-RT |
N0000020064
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2236
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
C61901
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
DB01278
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
70691388
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
C105254
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
PRAMLINTIDE
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
M9098
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | Merck Index | ||
|
151126-32-8
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
7448
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
SUB09993MIG
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
D3FM8FA78T
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
CHEMBL2103758
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
Pramlintide
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
7482
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | |||
|
139953
Created by
admin on Sat Jun 26 17:09:03 UTC 2021 , Edited by admin on Sat Jun 26 17:09:03 UTC 2021
|
PRIMARY | RxNorm |
From | To |
---|---|
1_2 | 1_7 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
|
||||
Molecular Formula | CHEMICAL |
|